SANUWAVE Health, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; filed May 14, 2012. SANUWAVE develops noninvasive PACE regenerative-medicine devices. It had no commercial products in the United States; revenue came from CE-marked devices and accessories sold in Europe, Canada, and Asia.
Financial performance
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $238,540 | $251,753 |
| Gross profit / margin | $166,768 / 70% | $158,455 / 63% |
| Operating expenses | $1,923,236 | $2,214,410 |
| Operating loss | $(1,756,468) | $(2,055,955) |
| Net loss / diluted loss per share | $(1,835,315) / $(0.09) | $(2,183,326) / $(0.14) |
| Net cash used in operations | $(1,490,445) | $(2,022,689) |
Revenue declined 5%, reflecting lower new-device sales to European distributors, partly offset by higher sales of higher-margin refurbishment applicators. Gross margin improved with higher applicator and wound-kit sales. R&D expense fell 19% to $603,797; G&A fell 10% to $1,237,540, although stock-based compensation increased to $262,176. Interest expense declined 67% to $78,856, largely because certain related-party notes were exchanged for equity in 2011. The prior-year quarter included $112,500 of transitional-services income from Pulse Veterinary Technologies; none was recorded in Q1 2012.
Balance sheet and liquidity
Cash and cash equivalents were $2,421,809 at March 31, 2012, down from $3,909,383 at year-end. Total assets were $4,585,341; total liabilities were $7,690,029, including $5,372,743 of related-party notes payable. The notes bear 6% interest and are due August 1, 2015. Current assets were $3,077,986 versus current liabilities of $2,309,601. Stockholders’ deficit was $3,104,688, and accumulated deficit was $66.3 million. Operating cash use was $1.49 million; cash decreased by $1.49 million during the quarter.
The company disclosed substantial doubt about its ability to continue as a going concern. Management said continued operations depend on additional financial support, which could include equity or debt financing, a strategic investment, asset sales, or other alternatives; financing may be unavailable or materially dilute shareholders. Management expected operating losses to continue for the next several years. The filing does not provide a specific cash-runway estimate.
Outlook, risks, and unusual items
- The dermaPACE Phase III trial did not meet its primary 12-week endpoint at the 95% confidence level: closure was 21% for treated patients versus 15% for sham control (p=0.363). Secondary analyses showed statistical significance at 20 weeks in the intent-to-treat population, but the FDA had issued a major deficiency letter and requested additional clinical work.
- The FDA conditionally approved an IDE supplement for an additional trial. Management estimated it could be completed and submitted in as early as 20 months from trial initiation, subject to successful results. Enrollment was expected as early as Q3 2012, contingent on IRB approvals and funding. An interim success analysis was projected after 90 patients completed the 12-week evaluation.
- SANUWAVE retained Canaccord Genuity to explore fundraising and strategic options to fund the additional clinical work. There is no assurance that financing will be obtained.
- In April 2012, shareholders approved increasing authorized common shares to 155 million; the company expected to file amended articles in May. This provides additional potential issuance capacity and may enable dilution.
- A former limited-partner lawsuit seeking more than $3 million received summary judgment in the company’s favor in December 2011; the plaintiff appealed in January 2012. Management said resolution of legal matters was not expected to materially harm financial position or results.
- The company reported $48.9 million of federal NOL carryforwards, beginning to expire in 2025; their use may be limited, including by ownership changes. The full deferred tax asset was subject to a valuation allowance.
Important facts for investors to verify
- Whether the company secures sufficient financing to support operations and the additional dermaPACE trial, and the terms and dilution involved.
- FDA feedback, trial start and enrollment timing, interim results, and whether the new study meets predefined success criteria.
- Cash burn and liquidity relative to available cash; the filing provides no clear cash-runway figure.
- Status and potential exposure from the appealed lawsuit and the $5.37 million related-party notes due in 2015.
- Potential shareholder dilution following the increase in authorized shares and from outstanding options and warrants.